Elanco Animal Health and Aratana Therapeutics Inc (NASDAQ:PETX) on Friday jointly reported the European Medicine Agency's (EMA) positive opinion for the recommendation of the marketing authorisation of GALLIPRANT (grapiprant tablets) in the EU for the treatment of pain associated with mild to moderate osteoarthritis in dogs.
The European Medicine Agency (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) has adopted a positive opinion to recommend the marketing authorisation of GALLIPRANT (grapiprant tablets) in the EU.
In early 2018, the European Commission will complete the regulatory process for a final decision on the Marketing Authorisation of GALLIPRANT, added the company.
According to the company, Galliprant is a first-in-class veterinary medicine that will be indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Grapiprant, the active ingredient in Galliprant, is a non-steroidal non-cyclooxygenase inhibiting anti-inflammatory drug.
Under the terms of a prior agreement, Elanco has exclusive rights to develop, manufacture, market and commercialise Galliprant globally and co-promotes the product with Aratana in the US.
Elanco Animal Health provides products and services to improve animal health and food-animal production and is a division of Eli Lilly and Company (NYSE:LLY).
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007